Shanghai Changzheng Hospital

🇨🇳China
Ownership
Private
Established
1955-01-01
Employees
-
Market Cap
-
Website
http://www.shczyy.com
Clinical Trials
Related News

Pancreatic Cancer and Diabetes Mellitus

Not yet recruiting
Conditions
Pancreatic Cancer
Surgery
Diabetes Mellitus
First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
150
Registration Number
NCT06585072

Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
500
Registration Number
NCT06585592

The Risk Factors and Its Prognosis of Hyperglycemia Secondary to Pancreatic Surgery

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
382
Registration Number
NCT06585046

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients

Early Phase 1
Not yet recruiting
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Drug: HNF4α srRNA
First Posted Date
2024-09-04
Last Posted Date
2024-09-04
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
9
Registration Number
NCT06583993

The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma

First Posted Date
2024-08-27
Last Posted Date
2024-08-27
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
20
Registration Number
NCT06572189
Locations
🇨🇳

Wen-Ping Xu, Shanghai, Shanghai, China

Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer

Recruiting
Conditions
Prostate Cancer
Interventions
Diagnostic Test: Blood draw
First Posted Date
2024-07-19
Last Posted Date
2024-12-12
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
1100
Registration Number
NCT06509919
Locations
🇨🇳

Changzheng hospital, Shanghai, Shanghai, China

The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension

Phase 2
Not yet recruiting
Conditions
Hypertension, Portal
Interventions
Drug: Alverine
First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
30
Registration Number
NCT06473493

The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis

Phase 2
Not yet recruiting
Conditions
Hypertension, Portal
Interventions
Drug: Alverine
Drug: Carvedilol
First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
178
Registration Number
NCT06470386

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients

Early Phase 1
Not yet recruiting
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Drug: CD-801
First Posted Date
2024-05-17
Last Posted Date
2024-08-28
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
37
Registration Number
NCT06418659

UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes

Not Applicable
Recruiting
Conditions
Newly Diagnosed Type 1 Diabetes Mellitus
Interventions
Drug: UCMSCs
Drug: Placebo
First Posted Date
2024-05-09
Last Posted Date
2024-05-09
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
24
Registration Number
NCT06407297
Locations
🇨🇳

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy